Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Alpha-1 antitrypsin (AAT) deficiency is well-suited as a target for human gene transfer. We performed a phase 1, open-label, dose-escalation clinical trial of a recombinant adeno-associated virus (rAAV) vector expressing normal (M) AAT packaged into serotype 1 AAV capsids delivered by i.m. injection. Nine AAT-deficient subjects were enrolled sequentially in cohorts of 3 each at doses of 6.9 × 10 12 , 2.2 × 10 13 , and 6.0 × 10 13 vector genome particles per patient. Four subjects receiving AAT protein augmentation discontinued therapy 28 or 56 days before vector administration. Vector administration was well tolerated, with only mild local reactions and 1 unrelated serious adverse event (bacterial epididymitis). There were no changes in hematology or clinical chemistry parameters. M-specific AAT was expressed above background in all subjects in cohorts 2 and 3 and was sustained at levels 0.1% of normal for at least 1 year in the highest dosage level cohort, despite development of neutralizing antibody and IFN-γ enzyme-linked immunospot responses to AAV1 capsid at day 14 in all subjects. These findings suggest that immune responses to AAV capsid that develop after i.m. injection of a serotype 1 rAAV vector expressing AAT do not completely eliminate transduced cells in this context.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, other trials have observed T-cell immune responses that did not clear transgene expression, particularly muscle-directed trials [86, 90, 91].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [90]
In the citing paper
“Despite the observation of immune responses after intravenous (i.v.) administration of AAV, concurrent clinical trials using intramuscular (i.m.) delivery of AAV revealed long-term transgene expression without immune suppression, regardless of significant immune cell infiltration.”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [7]
In the citing paper
“whereas muscle-directed AAV gene therapy clinical trials have shown long-lived transgene expression and induction of Tregs.7,8,11,51”
From Modulating immune responses to AAV by expanded polyclonal T-regs and capsid specific chimeric antigen receptor T-regulatory cells (2021) · cites this paper as [7]
In the citing paper
“have been implicated in contributing to long-term transgene expression in preclinical studies (35, 160, 161) and clinical trials (162 -164).”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [162]
Citations
Cites
Manno, C. S., Pierce, G. F., Arruda, V. R., Glader, B., Ragni, M., Rasko, J. J. E., Ozelo, M. C., Hoots, K., Blatt, P., Konkle, B., et al. (2006) · Nature Medicine · doi:10.1038/nm1358 · Cited by 2,163 · cited 2×
“This complexity also comes into play when comparing our data with that in the rAAV2–factor IX clinical trial (14).”
BackgroundResultHIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells
Betts, M. R. (2006) · Blood · doi:10.1182/blood-2005-12-4818 · Cited by 1,826
Self-citationNovel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy
Gao, G.-P., Alvira, M. R., Wang, L., Calcedo, R., Johnston, J., & Wilson, J. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.182412299 · Cited by 1,520 · cited 3×
“33, which is unexpected on the basis of animal immunization studies that indicate few shared B cell epitopes between these AAVs (18, 19).”
BackgroundInfluentialSelf-citationWorldwide epidemiology of neutralizing antibodies to adeno-associated viruses
Calcedo, R., Vandenberghe, L. H., Gao, G., Lin, J., & Wilson, J. M. (2009) · The Journal of Infectious Diseases · doi:10.1086/595830 · Cited by 808 · cited 1×
“Consistent with previously published results (16), antibodies to AAV7 and AAV8 were detected at baseline infrequently (in 2 of 9 subjects, both of whom had received the rAAV2 vector in a previous study) and antibodies to AAVrh32.”
ResultSelf-citationNovel Tools for Production and Purification of Recombinant Adenoassociated Virus Vectors
Grimm, D., Kern, A., Rittner, K., & Kleinschmidt, J. A. (1998) · Human Gene Therapy · doi:10.1089/hum.1998.9.18-2745 · Cited by 696 · cited 1×
“other Ad helper genes and the AAV1 rep and cap genes (23).”
BackgroundKessler, P. D., Podsakoff, G. M., Chen, X., McQuiston, S. A., Colosi, P. C., Matelis, L. A., Kurtzman, G. J., & Byrne, B. J. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.14082 · Cited by 614
Self-citationProduction and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors
Zolotukhin, S., Potter, M., Zolotukhin, I., Sakai, Y., Loiler, S., Fraites, T. J., Chiodo, V. A., Phillipsberg, T., Muzyczka, N., Hauswirth, W. W., et al. (2002) · Methods · doi:10.1016/s1046-2023(02)00220-7 · Cited by 565
Self-citationAdeno-associated viruses undergo substantial evolution in primates during natural infections
Gao, G., Alvira, M. R., Somanathan, S., Lu, Y., Vandenberghe, L. H., Rux, J. J., Calcedo, R., Sanmiguel, J., Abbas, Z., & Wilson, J. M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0937739100 · Cited by 323 · cited 3×
“33, which is unexpected on the basis of animal immunization studies that indicate few shared B cell epitopes between these AAVs (18, 19).”
BackgroundInfluentialSelf-citationSong, S., Morgan, M., Ellis, T., Poirier, A., Chesnut, K., Wang, J., Brantly, M., Muzyczka, N., Byrne, B. J., Atkinson, M., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.24.14384 · Cited by 304 · cited 1×
“Because of a marked efficiency advantage for vectors packaged in AAV serotype 1 capsid and injected in murine muscle, our group proceeded with preclinical development of a cross-packaged or pseudotyped rAAV–AAT vector, using the same rAAV–AAT gene cassette as in the previous clinical trial but packaged in a serotype 1…”
MethodSelf-citationThe Alpha1-antitrypsin Gene and Its Mutations
Crystal, R. G., Brantly, M. L., Hubbard, R. C., Curiel, D. T., States, D. J., & Holmes, M. D. (1989) · Chest · doi:10.1378/chest.95.1.196 · Cited by 209
Self-citation
Research works printed but not linked: 2
- 10.1016/s0002-9343(88)80069-x · doi:10.1016/s0002-9343(88)80069-x
- A Poirier, et al., Toxicology and biodistribution studies of a recombinant adeno-associated virus 2-α1-antitrypsin vector. Preclinica 2, 43–51 (2004).
Cited by
Items 201–300 of 349
rAAV Vector Product Characterization and Stability Studies
Snyder, R. O., Audit, M., & Francis, J. D. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-370-7_17 · Cited by 20
Cocaine Hydrolase Gene Therapy for Cocaine Abuse
Brimijoin, S., & Gao, Y. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.11.183 · Cited by 18
Gene Therapy in Skeletal Muscle Mediated by Adeno-Associated Virus Vectors
Qiao, C., Koo, T., Li, J., Xiao, X., & Dickson, J. G. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-370-7_5 · Cited by 18
The HLA class-II immunopeptidomes of AAV capsids proteins
Brito-Sierra, C. A., Lannan, M. B., Siegel, R. W., & Malherbe, L. P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1067399 · Cited by 17
“Different clinical trials have documented robust cellular immune responses developed by patients upon treatment with AAV (7, 8).”
BackgroundLarge-Scale Clinical Manufacturing of AAV Vectors for Systemic Muscle Gene Therapy
Clément, N. (2019) · Springer eBooks · doi:10.1007/978-3-030-03095-7_15 · Cited by 17
McNulty, M. J., Silberstein, D. Z., Kuhn, B. T., Padgett, H. S., Nandi, S., McDonald, K. A., & Cross, C. E. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.11.030 · Cited by 17
A quantitative PCR screening method for adeno‐associated viral vector 2‐mediated gene doping
Jiang, Z., Haughan, J. E., Moss, K. L., Stefanovski, D., Ortved, K. F., & Robinson, M. A. (2021) · Drug Testing and Analysis · doi:10.1002/dta.3152 · Cited by 17
Jiménez, V., Sacristan, V., Jambrina, C., Jaén, M. L., Casana, E., MUÑOZ, S. A., Marcó, S., Molas, M., García, M., Grass, I., et al. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.10.023 · Cited by 16
Michel, T., Kankura, A., Salinas Medina, M. L., Kurz, J., Behring, A., Avci-Adali, M., Nolte, A., Schlensak, C., Wendel, H. P., & Krajewski, S. (2015) · Nucleic Acid Therapeutics · doi:10.1089/nat.2015.0537 · Cited by 14
Rghei, A. D., van Lieshout, L. P., Cao, W., He, S., Tierney, K. J., Lopes, J. A., Zielinska, N., Baracuhy, E. M., Campbell, E. S. B., Minott, J. A., et al. (2022) · Gene Therapy · doi:10.1038/s41434-022-00361-2 · Cited by 16
“Indeed, there are many clinical trials in which AAV is administered to the muscle in multiple injections, in some cases as many as 90 injections [37], demonstrating a precedent for this approach [37, 49 – 51].”
Li, Z., Jayandharan, G. R., Aslanidi, G., Zolotukhin, S., Herzog, R. W., & Srivastava, A. (2012) · Journal of Genetic Syndromes & Gene Therapy · doi:10.4172/2157-7412.s1-008 · Cited by 17
“This is important in light of recent evidence suggesting that the level of neutralizing antibody is proportional to the vector dose administered for AAV1 [69], and the loss of hepatic h.FIX expression in the hemophilia B clinical trial was due to the CD8+ T cell response to input capsids in patients who received high…”
BackgroundInfluentialPassive Immunization against HIV/AIDS by Antibody Gene Transfer
Yang, L., & Wang, P. (2014) · Viruses · doi:10.3390/v6020428 · Cited by 16
“Thus, various serotypes of AAVs have become the most appealing vectors for in vivo gene therapy [46], and many of them have shown promising results in early-phase clinical trials [47–58].”
BackgroundTarantal, A. F., & Skarlatos, S. I. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.178 · Cited by 16
“In addition, the functional immaturity of the fetal immune system can overcome the barrier of immune responses that complicates gene transfer postnatally and in adults (Brantly et al ., 2009; Mays and Wilson, 2011).”
InfluentialLu, H., Qu, G., Yang, X., Xu, R., & Xiao, W. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.005 · Cited by 14
“Adeno-associated virus (AAV) vector has shown great promise as a gene therapy vector in human clinical trials (Manno et al., 2006; Brantly et al., 2009; Maguire et al., 2009; Mendell et al., 2010).”
Conlon, T. J., Mah, C. S., Pacak, C. A., Henninger, M. B. R., Erger, K. E., Jorgensen, M., Lee, C. C. I., Tarantal, A. F., & Byrne, B. J. (2016) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2016.119 · Cited by 15
Self-citationFakhiri, J., Landegger, L. D., & Grimm, D. (2020) · Hearing Research · doi:10.1016/j.heares.2020.108092 · Cited by 15
Gruntman, A. M., & Flotte, T. R. (2015) · Human Gene Therapy Methods · doi:10.1089/hgtb.2015.086 · Cited by 15
Self-citationAlpha-1 Antitrypsin Deficiency: New Developments in Augmentation and Other Therapies
Turner, A. M. (2013) · BioDrugs · doi:10.1007/s40259-013-0042-5 · Cited by 15
Redundancy in Innate Immune Pathways That Promote CD8+ T-Cell Responses in AAV1 Muscle Gene Transfer
Li, N., Kumar, S. R. P., Cao, D., Muñoz-Melero, M., Arisa, S., Brian, B. A., Greenwood, C. M., Yamada, K., Duan, D., & Herzog, R. W. (2024) · Viruses · doi:10.3390/v16101507 · Cited by 14
“AAV1 has since been evaluated in multiple clinical trials in skeletal muscle, cardiac, and diaphragm gene transfer for the treatment of a variety of inherited and acquired diseases [1,2,49–54].”
BackgroundPhoenix rising: gene therapy makes a comeback
Limberis, M. P. (2012) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gms036 · Cited by 14
“Significant frequencies of circulating transgene-specific T cells have been reported in subjects treated with AAV vectors for various diseases including A1AT deficiency [114] and DMD [116] .”
BackgroundImmunosuppression Decreases Inflammation and Increases AAV6-hSERCA2a-Mediated SERCA2a Expression
Zhu, X., McTiernan, C. F., Rajagopalan, N., Shah, H., Fischer, D., Toyoda, Y., Letts, D. P., Bortinger, J., Gibson, G. A., Xiang, W., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2011.108 · Cited by 14
Zhang, X., Pham, K., Li, D., Schutte, R. J., Gonzalo, D. H., Zhang, P., Oshins, R. A., Tan, W., Brantly, M., Liu, C., et al. (2019) · Cells · doi:10.3390/cells8121586 · Cited by 13
“Gene therapy is a promising strategy to treat AATD [20,24], although approved approaches are currently unavailable [25,26].”
BackgroundSelf-citationAdeno-Associated Virus–Mediated Gene Therapy for Metabolic Myopathy
Mah, C. S., Soustek, M. S., Todd, A. G., McCall, A. L., Smith, B. K., Corti, M., Falk, D. J., & Byrne, B. J. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.2514 · Cited by 13
“…phase I/II study to administer AAV2/ 1-CMV-hGAA by direct intramuscular injection to the diaphragm of ventilator-dependent Pompe children has been initiated at the University of Florida (clinicaltrials.gov, identifier NCT00976352) (Stroes et al., 2008; Brantly et al., 2009; Mendell et al., 2009).”
BackgroundSelf-citationPromise of adeno-associated virus as a gene therapy vector for cardiovascular diseases
Bera, A., & Sen, D. (2017) · Heart Failure Reviews · doi:10.1007/s10741-017-9622-7 · Cited by 14
Brimijoin, S. (2011) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152711799219398 · Cited by 13
“As a result, and despite the drawbacks just noted, over a dozen clinical trials have been completed with AAV vectors, focusing on multiple diseases such as alpha 1 antitrypsin deficiency [93], hemophilia B [94], cystic fibrosis [95], Parkinson’s disease [96], heart failure [97], and rheumatoid arthritis [98], and more…”
BackgroundTherapeutics: Gene Therapy for Alpha-1 Antitrypsin Deficiency
Gruntman, A. M., & Flotte, T. R. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7163-3_27 · Cited by 13
Self-citationImmune Toxicities in AAV Gene Therapy: Overview for Clinicians
Parajuli, S., Gallagher, T. L., & Flotte, T. R. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27073196 · Cited by 12
“…packaged in an AAV1 capsid via IM injection at doses of 6.9 × 10 12 , 2.2 × 10 13 , and 6.0 × 10 13 , and then monitored immune responses using interferon (IFN)- γ enzyme-linked immunospot (ELISPOT) assays, lymphocyte proliferation assays, and serum antibody measurements against AAV1 capsid [35].”
InfluentialSelf-citationTai, D. S., Hu, C., Lee, C. C. I., Martinez, M. L., Cantero, G., Kim, E. H., Tarantal, A. F., & Lipshutz, G. S. (2015) · Gene Therapy · doi:10.1038/gt.2015.65 · Cited by 12
Abdel‐Motal, U. M., Harbison, C., Han, T., Pudney, J. A., Anderson, D. J., Zhu, Q. K., Westmoreland, S. V., & Marasco, W. A. (2014) · Gene Therapy · doi:10.1038/gt.2014.56 · Cited by 13
Alpha-1 Antitrypsin Deficiency and Accelerated Aging: A New Model for an Old Disease?
Crossley, D., Stockley, R. A., & Sapey, E. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00684-7 · Cited by 12
Janosz, E., Hetzel, M., Spielmann, H., Tumpara, S., Rossdam, C., Schwabbauer, M., Kloos, D., von Kaisenberg, C., Schambach, A., Buettner, F. F. R., et al. (2021) · Gene Therapy · doi:10.1038/s41434-021-00269-3 · Cited by 12
Zieger, M. V., Borel, F., Greer, C., Gernoux, G., Blackwood, M., Flotte, T. R., & Mueller, C. (2022) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2022.04.003 · Cited by 12
Self-citationRecombinant Adeno-Associated Viral Vector Reference Standards
Moullier, P., & Snyder, R. O. (2012) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-386509-0.00015-6 · Cited by 11
Wu, Y., Lin, X., Hong, H., Fung, Y. L., Cao, X., Tse, J. K. Y., Li, T. H., Chan, T., & Tian, X. Y. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113172 · Cited by 11
Mueller, C., Keeler, A. M., Braag, S. A., Menz, T., Tang, Q., & Flotte, T. R. (2009) · Molecular Therapy · doi:10.1038/mt.2009.264 · Cited by 11
Self-citationCircumventing B Cell Responses to Allow for Redosing of Adeno-Associated Virus Vectors
Ertl, H. C. J. (2024) · Human Gene Therapy · doi:10.1089/hum.2023.162 · Cited by 10
“55 Others have shown that the immunosuppressive effects of rapamycin in part relate to its effect on cell metabolism that favors inductions of Tregs over stimulation of effector T cell subsets.”
Autoimmunity in a Genetic Disease — A Cautionary Tale
Moore, M. J., & Flotte, T. R. (2010) · New England Journal of Medicine · doi:10.1056/nejme1009056 · Cited by 10
Self-citationDéficit de alfa-1 antitripsina
Dasí, F. (2022) · Medicina Clínica · doi:10.1016/j.medcli.2022.09.001 · Cited by 10
Ke, H., Guay, K. P., Flotte, T. R., Gierasch, L. M., Gershenson, A., & Hebert, D. N. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2206103119 · Cited by 9
“Human trials involving multiple numerous intramuscular injections using AAV-based platforms for the expression of wildtype AAT in patients with AAT deficiency due to the AAT-Z mutation showed wild-type AAT production (29, 82), which even 5 y after injection was sustained at 2.”
BackgroundSelf-citationIncreased expression or activation of TRPML1 reduces hepatic storage of toxic Z alpha-1 antitrypsin
Pastore, N., Annunziata, F., Colonna, R., Maffia, V., Giuliano, T., Custode, B. M., Lombardi, B., Polishchuk, E., Cacace, V., Stefano, L. D., et al. (2023) · Molecular Therapy · doi:10.1016/j.ymthe.2023.06.018 · Cited by 9
Ghosh, A., & Hobbs, B. D. (2022) · Expert Review of Respiratory Medicine · doi:10.1080/17476348.2022.2027755 · Cited by 9
“modest efficacy in raising serum AAT levels but were plagued by the immune-related side effects or waning efficacy, while others showed no evidence of efficacy [77,78].”
BackgroundGene Therapy for Rett Syndrome: Prospects and Challenges
Gadalla, K. K. E., Ross, P. D., Hector, R. D., Bahey, N. G., Bailey, M. E. S., & Cobb, S. (2015) · Future Neurology · doi:10.2217/fnl.15.29 · Cited by 9
Pastore, N., Nusco, E., Jašprová, J., Sepe, R. M., Vetrini, F., McDonagh, A. F., Auricchio, A., Vítek, L., & Brunetti‐Pierri, N. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.018 · Cited by 9
“…AAV2/1 vectors in patients with a 1 -antitrypsin deficiency showed long-term gene expression despite evidence of an immune response to AAV1 capsids (Brantly et al. , 2009), suggesting the presence of a cytotoxic T lymphocyte (CTL) response to AAV capsids that does not result in the elimination of…”
Journou, M., Devaux, M., Jaulin, N., Pichard, V., Segovia, M., Moreau, A., Duff, J. L., Cuturi, M. C., Guilbaud, M., & Adjali, O. (2025) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2025.101409 · Cited by 8
A cure for alpha-1? Novel therapeutics in alpha-1 antitrypsin deficiency
Alluhibi, R., Marshall, A., Lomas, D. A., & Hurst, J. R. (2025) · European Respiratory Journal · doi:10.1183/13993003.01101-2025 · Cited by 8
Herdt, A. R., Peng, H. C., Dickson, D. W., Golde, T. E., Eckman, E. A., & Lee, C. W. (2023) · Genes · doi:10.3390/genes14081517 · Cited by 8
“AAV1 vector-mediated gene therapy has been used in several human clinical studies, including the treatment of lipoprotein lipase deficiency [33], antitrypsin deficiency [34], and muscular dystrophy [35].”
MethodDevelopment, validation and use of ELISA for antibodies to human alpha-1 antitrypsin
Ye, G.-J., Oshins, R. A., Rouhani, F. N., Brantly, M., & Chulay, J. D. (2012) · Journal of Immunological Methods · doi:10.1016/j.jim.2012.11.008 · Cited by 8
“, 2011) and has been administered to AAT-deficient patients in clinical trials (Brantly et al., 2009; Flotte et al., 2011).”
MethodInfluentialSelf-citationAlpha-1 antitrypsin deficiency
Dasí, F. (2024) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2023.10.026 · Cited by 7
Carrig, S., Bijjiga, E., Wopat, M. J., & Martino, A. T. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.073 · Cited by 7
A compact base editor rescues AATD-associated liver and lung disease in mouse models
Gao, J., Bamidele, N., Pires-Ferreira, D., Zheng, C., Destefano, A., Cheng, H., Tang, Q., Cao, Y., Xie, J., Gao, G., et al. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.08.040 · Cited by 6
Self-citationAdministration and detection of gene therapy in horses: A systematic review
Haughan, J. E., Ortved, K. F., & Robinson, M. A. (2022) · Drug Testing and Analysis · doi:10.1002/dta.3394 · Cited by 6
Pharmacodynamics of anti-HIV gene therapy using viral vectors and targeted endonucleases
Roychoudhury, P., Feelixge, H. S. D. S., Pietz, H. L., Stone, D., Jerome, K. R., & Schiffer, J. T. (2016) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkw104 · Cited by 6
Gene Therapy in Tyrosinemia: Potential and Pitfalls
Carter, S., & Doyon, Y. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-55780-9_21 · Cited by 6
Autoimmunity, Recessive Diseases, and Gene Replacement Therapy
Wilson, J. M. (2010) · Molecular Therapy · doi:10.1038/mt.2010.253 · Cited by 6
Self-citationZhang, T., & Zou, P. (2023) · The AAPS Journal · doi:10.1208/s12248-023-00867-6 · Cited by 5
“At various IM doses, serum AAT levels were found dose-dependent in preclinical species (18, 20) and humans (19, 21).”
BackgroundAfrin, S., Hasan, T. B., Sagar, M. T. A., Naima, T., Maisha, S., Yeasmin, S., Masud, A. A., & Akter, F. (2025) · Cureus · doi:10.7759/cureus.79286 · Cited by 5
“In Phase 1 trials (2009), nine patients received AAV1, experiencing mild injection-site reactions and transient vector DNA in blood [9].”
InfluentialSmall Molecule-Based Inducible Gene Therapies for Retinal Degeneration
Datta, S., Peng, H., & Hulleman, J. D. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-27378-1_11 · Cited by 5
Viral vectors engineered for gene therapy
Lundstrom, K. H. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2023.05.005 · Cited by 5
Choudhary, V. (2022) · BULLET : Jurnal Multidisiplin Ilmu · Cited by 5
Analyzing Cellular Immunity to AAV in a Canine Model Using ELISPOT Assay
Wang, Z., Storb, R. F., Tapscott, S. J., & Riddell, S. R. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-325-7_5 · Cited by 5
Yu, Y., Fu, L., Jiang, X., Guan, S., Kuai, Z., Kong, W., Shi, Y., & Shan, Y. (2016) · Molecular Immunology · doi:10.1016/j.molimm.2016.10.011 · Cited by 5
AAV Vector-Based Gene Therapy, Progress and Current Challenges
Kuranda, K., & Mingozzi, F. (2017) · Springer eBooks · doi:10.1007/978-3-319-53457-2_5 · Cited by 5
Gene Delivery of Alpha-1-Antitrypsin Using Recombinant Adeno-Associated Virus (rAAV)
Song, S., & Lu, Y. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8645-3_12 · Cited by 5
In Cellulo Fabrication of Supramolecular Protein Assemblies
Yang, H., Song, C. W., Lu, J., & Lin, D. (2026) · Chemical Reviews · doi:10.1021/acs.chemrev.5c01095 · Cited by 4
Delivery of Adeno-Associated Virus Gene Therapy by Intravascular Limb Infusion Methods
Gruntman, A. M., & Flotte, T. R. (2015) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2015.116 · Cited by 4
Self-citationBerberine potentiates liver inflammation and fibrosis in the PI*Z hAAT transgenic murine model
Lu, Y., Mohammad, N. S., Lee, J., Aranyos, A. M., Serban, K. A., & Brantly, M. (2024) · PLoS ONE · doi:10.1371/journal.pone.0310524 · Cited by 4
“The hAAT concentration in cell culture medium was measured by ELISA as previously described [32].”
MethodSelf-citationA Barrel of Monkeys: scAAV8 Gene Therapy for Hemophilia in Nonhuman Primates
Chandler, R. J., & Venditti, C. P. (2011) · Molecular Therapy · doi:10.1038/mt.2011.73 · Cited by 4
Blackwood, M., Gruntman, A. M., Tang, Q., Pires-Ferreira, D., Reil, D., Kondratov, O., Marsic, D., Zolotukhin, S., Gernoux, G., Keeler, A. M., et al. (2024) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2024.101200 · Cited by 4
Self-citationRecombinant Adeno-Associated Virus Serotype 6 Efficiently Transduces Primary Human Melanocytes
Sheppard, H. M., Ussher, J. E., Verdon, D. J., Chen, J. H., Taylor, J. A., & Dunbar, P. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062753 · Cited by 4
“It has been extensively evaluated as a gene therapy vector with hundreds of patients having received rAAV in clinical trials without any significant vector-associated complications [21,22,23,24,25,26].”
BackgroundSutter, M., Cremona, T. P., Nita, I., Cavarra, E., Lungarella, G., Lewis, E. C., Schittny, J. C., Geiser, T., & Gazdhar, A. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12090793 · Cited by 4
“For clinical trials, however, different serotypes of AAV have been used [33,34] by either intramuscular or intrapleural routes.”
MethodWhat Is Suppression of Anti–Adeno-Associated Virus Capsid T-Cells Achieving?
Flotte, T. R., & Mueller, C. (2014) · Human Gene Therapy · doi:10.1089/hum.2014.2506 · Cited by 4
“Two successive studies have demonstrated that vector expression persists for at least a year despite effector T-cell responses (Brantly et al ., 2009; Flotte et al ., 2011).”
Self-citationHenry, T. D., Chung, E. S., Alvisi, M., Murray, D. R. P., Traverse, J. H., Roessig, L., Roberts, L., Sanganalmath, S. K., Reddy, S., Ervin, L., et al. (2026) · European Journal of Heart Failure · doi:10.1093/ejhf/xuag105 · Cited by 3
Recent Advances in Designing Adeno-Associated Virus-Based Vaccines Against Viral Infections
Mnyandu, N., Jacobs, R., Arbuthnot, P. B., & Maepa, M. B. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16111360 · Cited by 3
Zhang, X., Santos, R. G., Debevec, G., Li, D., Schutte, R. J., Pham, K., Liu, C., Ostrov, D. A., & Giulianotti, M. A. (2020) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2020.04.037 · Cited by 3
Reactions of Muscle to Toxins and Drugs
Aronica, E., & Stenzel, W. (2013) · Wiley eBooks · doi:10.1002/9781118635469.ch37 · Cited by 3
Preclinical Study Design for rAAV
Flotte, T. R., Conlon, T. J., & Mueller, C. (2011) · Methods in molecular biology · doi:10.1007/978-1-61779-370-7_14 · Cited by 3
Self-citationBeletić, A. D., Dudvarski-Ilić, A., Milenkovic, B. A., Nagorni-Obradović, L. M., Ljujić, M., Djordjevic, V. J., Radojkovic, D. P., & Majkić‐Singh, N. (2013) · Journal of Medical Biochemistry · doi:10.2478/jomb-2013-0038 · Cited by 3
Efficient, Specific and Targeted Delivery of Genes to the Lung
Pfeifer, C., Himmel, A., Geiger, J.-P., Aneja, M. K., & Rudolph, C. (2010) · Therapeutic Delivery · doi:10.4155/tde.10.11 · Cited by 3
Treatment of lung disease in patients with AATD
Ellis, P., Dirksen, A., & Turner, A. M. (2019) · European Respiratory Society eBooks · doi:10.1183/2312508x.10032718 · Cited by 3
Challenges Posed by Gene Manipulations and Sport Performance
Cohen‐Haguenauer, O. (2021) · Springer eBooks · doi:10.1007/978-3-030-79293-0_4 · Cited by 3
Flotte, T. R., Blackwood, M., Arjomandnejad, M., Harkins, A. L., Sylvia, K., Iyer, S., Kokoski, D., Artinian, R., & Keeler, A. M. (2025) · medRxiv · doi:10.1101/2025.05.07.25327170 · Cited by 3
“Induction of Tregs after delivery of AAV has been previously described after muscle delivery and is associated with stable transgene expression[27-30].”
Self-citationIntramuscular Injection of rAAV2-retro for Low Motor Neuron Transduction: Evaluating Five Promoters
Gong, X., Gao, H., Wang, W., & Xu, T. (2025) · International Journal of Medical Sciences · doi:10.7150/ijms.101807 · Cited by 2
Gene Therapy for Heart Failure: Impact on Mitochondrial Dysfunction
Blagonravov, M. L., Sklifasovskaya, A. P., Karpov, R. M., Ovechkina, V. S., Andrianova, S. K., Syatkin, S. P., Belousov, V. V., & Mozhaev, A. A. (2026) · Biomedicines · doi:10.3390/biomedicines14020344 · Cited by 2
“However, a significant cytotoxic CD8+ T-cell response to the AAV capsid is predominantly observed in the liver [110], in contrast, muscle tissue demonstrates a notable resistance to the elimination of transgene-expressing cells [98,111].”
Alvisi, M., Roberts, L., Roessig, L., Balderson, D. E., Sanganalmath, S. K., Braun, M., Gordon, S. N., Lacey, S. F., Pandya, P., & Hajjar, R. J. (2026) · Human Gene Therapy · doi:10.1177/10430342261430244 · Cited by 2
“…a limited number of trials administering IV or intramuscular doses did not select based on the pre-existing anti-AAV Ab titers (Table 2), 22,34,36,54 – 60 setting a precedent for assessing the potential bene fi t of AAV GT treatment against the potential risks associated with pre-existing…”
Alpha-1 Antitrypsin Deficiency-Associated Chronic Obstructive Pulmonary Disease
Fouka, E., Vrouvaki, A., Christodoulou, M., Loukides, S., & Hillas, G. (2026) · Medicina · doi:10.3390/medicina62040639 · Cited by 2
“…phase clinical trials using recombinant adeno-associated viral (rAAV) vectors for gene transfer have demonstrated safety; however, they only achieved AAT expression levels below the therapeutic threshold, indicating the need for further optimizing vector dosing and expression efficiency [111,112].”
Strategies for Evading Cellular Immunity Against Recombinant AAV Vectors in Gene Therapy
Wang, Z., Wu, X., Fu, D.-Y., Li, X., Liu, D., Liu, S., Zhao, Q., & Wang, H. (2026) · Current Medical Science · doi:10.1007/s11596-026-00178-9 · Cited by 2
Jiménez, V., Sacristan, V., García, M., Jambrina, C., Casana, E., MUÑOZ, S. A., Vilà, L., Grass, I., Jaén, M. L., Roca, C., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.05.025 · Cited by 3
Pires-Ferreira, D., Reil, D., Tang, Q., Blackwood, M., Gallagher, T. F., Keeler, A. M., Chichester, J. A., Vyhnal, K. K., Lindborg, J. A., Benson, J. M., et al. (2024) · Genes · doi:10.3390/genes15091188 · Cited by 2
Self-citationSurgical and Bronchoscopic Lung Volume Reduction Treatment for α-1 Antitrypsin Deficiency
Rokadia, H. K., & Stoller, J. K. (2015) · Clinical Pulmonary Medicine · doi:10.1097/cpm.0000000000000116 · Cited by 2
Modes of allergy and total IgE concentrations among various ages of Basrah populations
Alsaimary, I. E. (2011) · International Research Journal of Microbiology · Cited by 2
Muscle-Directed Gene Therapy for Alpha-1 Antitrypsin Deficiency
Gruntman, A. M., & Flotte, T. R. (2019) · Springer eBooks · doi:10.1007/978-3-030-03095-7_45 · Cited by 2
Self-citationTurner, A. M. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803942-7.00014-3 · Cited by 2
Muscle as a Metabolic Factory for Gene Therapy
Mah, C. S., Pacak, C. A., & Byrne, B. J. (2009) · Springer eBooks · doi:10.1007/978-1-4419-1207-7_13 · Cited by 2
“They surmised that these data indicate that direct delivery of the muscle gene into mature muscle cells may be a more suitable strategy for treatment of this disease than implantation of adenovirus-engineered myoblasts ( Baque et al. 1994 ).”
BackgroundSelf-citationGhenassia, A. (2015) · theses.fr (ABES) · doi:10.70675/258b493cz74a9z4788zbbb4za8046cd94fe0 · Cited by 2
“…telles observations ont pu également être faites lorsque le muscle était ciblé par ces vecteurs dans le cadre d’études cliniques de thérapie génique (Brantly et al., 2009; Flotte et al., 2005, 2011; Herson et al., 2012; Jaski et al., 2009; Mendell et al., 2009, 2010a, 2010b; Mingozzi et al., 2009).”
BackgroundAlpha-1 Antitrypsin Deficiency in Children. A Modern View of the Problem
Вениаминовна, В. И., Fedotova, G., Timofeevа, M. S., & Timofeev, E. S. (2024) · Ural Medical Journal · doi:10.52420/umj.23.6.132 · Cited by 1
Taming immune responses to AAV gene therapy by programmed in vivo Treg expansion
Gwalani, L. A., Park, M., Ysasi, A. B., Motwani, M., Jackson, R., Bu, J., Luo, Z., Bladon, J. H., Pfister, E. L., Mueller, C., et al. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.02.019 · Cited by 1
“21 AAV1-mediated delivery of human α -1 antitrypsin (AAT) by intra-muscular injection resulted in sustained AAT expression for up to 5 years.”
Self-citationRewriting hepatic fate: emerging gene therapy strategies for liver disease
Weiskirchen, R. (2026) · Journal of Translational Genetics and Genomics · doi:10.20517/jtgg.2026.36 · Cited by 1
Gene Therapy for Alpha-1-Antitrypsin Deficiency Diseases
Salahuddin, P. (2011) · InTech eBooks · doi:10.5772/17415 · Cited by 1
“…has several advantages over other approaches , such as a more favorable profile of anti-capsid effector T-cell responses (Manno et al., 2006; Brantly et al., 2009) and a lower www.intechopen.com Gene Therapy Application 386 level of dissemination to distant sites (Manno et al., 2003; 2006).”
Bruce-Hickman, D., Greene, C. M., & Gooptu, B. (2015) · European Respiratory Society eBooks · doi:10.1183/2312508x.10018214 · Cited by 1
Viral Gene Transfer of Enzymes
Brimijoin, W. S. (2015) · Springer eBooks · doi:10.1007/978-3-319-23150-1_11 · Cited by 1
Metadata
- Authors
- Brantly, M. L., Chulay, J. D., Wang, L., Mueller, C., Humphries, M., Spencer, L. T., Rouhani, F., Conlon, T. J., Calcedo, R., Betts, M. R., Spencer, C., Byrne, B. J., Wilson, J. M., & Flotte, T. R.
- Affiliations
- University of Florida (US)
- Applied Genetic Technologies (United States) (US)
- University of Pennsylvania (US)
- University of Massachusetts Chan Medical School (US)
- Boston Children's Hospital (US)
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2009-09-22
- Volume
- 106
- Issue
- 38
- Pages
- 16363-16368
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2752529
- OpenAlex
- W2083867423
- Cited by
- 327
- References
- 31
- Citations by year
- 2026: 12 · 2025: 8 · 2024: 13 · 2023: 16 · 2022: 17 · 2021: 13 · 2020: 11 · 2019: 16 · 2018: 12 · 2017: 20 · 2016: 21 · 2015: 19 · 2014: 24 · 2013: 24 · 2012: 27
- FWCI
- 19.19
- Type
- journal article
- Language
- en
- Update notices
- correction (2009-10-13)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- The Journal of the American Medical Association (JAMA) Network (American Medical Association) (submittedVersion)
- Funders
- University of Florida
- Applied Genetic Technologies Corporation
- National Institutes of Health (and K24, DK047757)
- National Heart, Lung, and Blood Institute (R01HL69877, P01HL059412, R01HL069877, K24HL004456, K24 HL004456-5)
- National Institute of Diabetes and Digestive and Kidney Diseases (P01DK058327, P30DK047757, DK58327, DK047757-15)
- National Center for Research Resources (U42RR016586, M01RR000082)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- alpha-1 antitrypsin deficiency, T cell response, neutralizing antibodies, interferon-gamma, sustained transgene expression, dose escalation
- MeSH terms
- Dependovirus, Adult, Aged, alpha 1-Antitrypsin, Antibodies, Viral, Capsid, Cell Line, Enzyme-Linked Immunosorbent Assay, Female, Genetic Vectors, Humans, Injections, Intramuscular, Male, Middle Aged, Recombinant Fusion Proteins, T-Lymphocytes, Time Factors, Genetic Therapy, CD4-Positive T-Lymphocytes, Gene Expression, CD8-Positive T-Lymphocytes, alpha 1-Antitrypsin Deficiency
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.